SG160342A1 - Inhibition or treatment of dyskinesia - Google Patents

Inhibition or treatment of dyskinesia

Info

Publication number
SG160342A1
SG160342A1 SG201001316-7A SG2010013167A SG160342A1 SG 160342 A1 SG160342 A1 SG 160342A1 SG 2010013167 A SG2010013167 A SG 2010013167A SG 160342 A1 SG160342 A1 SG 160342A1
Authority
SG
Singapore
Prior art keywords
treatment
dyskinesia
inhibition
dopa
effected
Prior art date
Application number
SG201001316-7A
Other languages
English (en)
Inventor
Mahmoud Irvani
Peter Jenner
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0503540A external-priority patent/GB0503540D0/en
Priority claimed from GB0508843A external-priority patent/GB0508843D0/en
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of SG160342A1 publication Critical patent/SG160342A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG201001316-7A 2005-02-21 2006-02-20 Inhibition or treatment of dyskinesia SG160342A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0503540A GB0503540D0 (en) 2005-02-21 2005-02-21 Inhibition or treatment of dyskinesia
GB0508843A GB0508843D0 (en) 2005-04-29 2005-04-29 Inhibition or treatment of dyskinesia

Publications (1)

Publication Number Publication Date
SG160342A1 true SG160342A1 (en) 2010-04-29

Family

ID=36691702

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201001316-7A SG160342A1 (en) 2005-02-21 2006-02-20 Inhibition or treatment of dyskinesia

Country Status (6)

Country Link
US (1) US20080070952A1 (enExample)
EP (1) EP1850838A2 (enExample)
JP (1) JP2008545616A (enExample)
CA (1) CA2598484A1 (enExample)
SG (1) SG160342A1 (enExample)
WO (1) WO2006087577A2 (enExample)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0891332B1 (en) * 1996-03-29 2004-03-17 Pfizer Inc. 6-phenylpyridyl-2-amine derivatives
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
KR100460399B1 (ko) * 1997-02-10 2004-12-08 화이자 프로덕츠 인코포레이티드 2-아미노-6-(2-치환된-4-페녹시)-치환된-피리딘
WO1998048826A1 (en) * 1997-04-30 1998-11-05 Northwestern University Inhibition of nitric oxide synthase by amino acids and dipeptides
WO2003000198A2 (en) * 2001-06-22 2003-01-03 Northwestern University Selective neuronal nitric oxide synthase inhibitors
US20030232739A1 (en) * 2001-08-15 2003-12-18 Pfizer Inc. Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
DOP2002000467A (es) * 2001-10-10 2003-04-15 Pfizer Prod Inc 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas
US6803470B2 (en) * 2001-10-10 2004-10-12 Pfizer Inc 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
EP1670478A4 (en) * 2003-09-08 2009-05-06 Univ Northwestern HETEROAROMATIC SELECTIVE INHIBITORS OF NEURONAL STITCHOXIDE SYNTHASE

Also Published As

Publication number Publication date
WO2006087577A2 (en) 2006-08-24
WO2006087577A3 (en) 2006-10-19
JP2008545616A (ja) 2008-12-18
US20080070952A1 (en) 2008-03-20
CA2598484A1 (en) 2006-08-24
EP1850838A2 (en) 2007-11-07

Similar Documents

Publication Publication Date Title
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
IL197090A (en) A method for the identification of inhibitors of glutaminyl cyclase variants
IL192634A0 (en) Thiazoles as 11 beta-hsd1 inhibitors
IL192603A0 (en) Thieno-pyridine derivatives as mek inhibitors
IL196989A0 (en) Cyclic ii-?? hydroxysteroid dehydrogenase type 1 inhibitors
PL2101759T3 (pl) Sposoby stosowania inhibitorów MEK
IL194868A0 (en) Inhibitors of the task-1 and task-3 ion channel
ZA200809689B (en) 1, 3, 4 -Oxadiazole derivatives as DGAT1 inhibitors
TW200745094A (en) ATM inhibitor
WO2010093787A3 (en) Aminopyridine dimer compounds, compositions and related methods for neuronal nitric oxide synthase inhibition
ZA200807357B (en) Inhibitors of PAI-1 for treatment of muscular conditions
JO2730B1 (en) Medications for the treatment of endometriosis
IL185382A0 (en) Multimediator dopamine transport inhibitors, and uses related thereto
SG160342A1 (en) Inhibition or treatment of dyskinesia
PH12014500538A1 (en) Methods and compositions for treating leukemia
ZA200908771B (en) Cysteine protease inhibitors
IL173706A0 (en) Corrosion inhibitors
WO2008087163A3 (en) Method, use and agent for protecting a plant against pythium and rhizoctonia
GB2467748B8 (en) Writing instrument and handcuff accessory and method.
WO2008125989A3 (en) Polyketide based proteasome inhibitor
ZA200808171B (en) Inhibitors of the task-1 and task-3 ion channel
EP1996195A4 (en) HYDROXYLAMINES AND DERIVATIVES FOR THE INHIBITION OF COMPLEMENT ACTIVATION
GB0703043D0 (en) Cysteine protease inhibitors
GB0712172D0 (en) Cysteine protease inhibitors
GB0712193D0 (en) Cysteine protease inhibitors